INAB IN8bio, Inc. Common Stock

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

INAB — —
Key stats
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
18
List Date
2021-07-30
CIK
0001740279
Next Earnings
2026-11-05
EPS Forecast
($0.57) (1 est.)
Headquarters
New York, NY
Homepage
https://www.in8bio.com

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in a…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan---21.99%-2.30%-1.52%-8.71%-19.92%-10.89%
Feb--17.32%-36.78%-7.50%7.21%-13.27%-6.60%
Mar---19.17%-19.75%8.26%-36.15%-12.94%-15.95%
Apr---30.23%10.61%-11.30%-2.14%5.00%-5.61%
May---1.77%74.71%14.42%-12.77%24.67%19.85%
Jun--0.89%-49.67%-22.34%-47.89%-18.50%-27.50%
Jul0.00%14.41%-28.92%3.30%2.90%-27.62%-5.99%
Aug-32.00%8.82%-19.85%-38.07%4.74%14.58%-10.30%
Sep1.33%-30.10%-1.89%-46.01%-1.81%22.02%-9.41%
Oct2.71%-4.88%-5.78%8.98%-13.72%-31.04%*-7.29%
Nov-24.39%-10.77%-15.31%6.39%5.32%---7.75%
Dec-20.18%7.44%63.22%-30.11%19.39%--7.95%
Total-57.29%-59.41%-64.90%-78.25%-68.08%-54.98%-63.82%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $1.23
SMA 50: $1.17
SMA 200: $1.48
Current: $0.97
EMA 12: $1.11
EMA 26: $1.16
MACD: -0.0485 | Signal: -0.0363
BEARISH
ADX (14): 32.04
TREND
+DI: 8.60
−DI: 36.07

Momentum Oscillators

RSI (14): 34.88
NEUTRAL
Stoch %K: 11.82
Stoch %D: 10.54
Williams %R: -82.31

Volume & Volatility

BB Upper: $1.52
BB Lower: $0.94
NEUTRAL
OBV: -9,756,841
Vol SMA 20: 46,631
Vol ROC: 366.67%
ATR: $0.10
True Range: $0.18
HV 20: 75.6%
HV 30: 76.8%
HV 60: 83.3%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

Here is the comprehensive stock analysis report for INAB:

Executive Summary

Overall Assessment: BEARISH (confidence level: 6/10)

Key Drivers: Recent negative market sentiment, high volatility, and mixed technical signals.

Primary Risks: High risk due to beta >1.5, moderate to high volatility, and mixed news sentiment.

Investment Thesis: INAB is a high-risk stock with potential for significant price movements. The recent positive news headlines have been offset by bearish technical signals, indicating a cautionary approach is necessary.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Bearish
  • Medium-term (1-3 months): Neutral
  • Long-term (3-12 months): Bullish

Support/Resistance Levels:

  • SMA 20: $1.13 (support)
  • SMA 50: $1.20 (neutral)
  • SMA 200: $1.60 (resistance)

Momentum Signals:

  • RSI interpretation: Neutral (54.93) - not oversold or overbought
  • MACD signal: Bearish (negative histogram and signal line crossover)
  • Bollinger Bands position: Squeeze - price is near the middle band

News & Sentiment Analysis

Recent Headlines Summary: The recent news headlines are primarily positive, highlighting clinical trial results, new market entries, and leadership appointments.

Sentiment Assessment: Positive (aggregate sentiment from last 10 news articles)

Catalyst Identification:

  • Upcoming events: No significant earnings or product launches scheduled
  • Earnings data: Not available

Risk & Volatility Assessment

Beta Interpretation: High risk due to beta >1.5, indicating more volatility than the market.

Volatility Regime: Current vs historical volatility levels: Moderate to high (101.1% HV20)

Options Market Signals: No options data available

Downside Protection: Support levels at SMA 20 ($1.13) and potential for mean reversion

Market Context & Positioning

Sector Performance: INAB is part of the Biotech sector, which has been experiencing moderate growth.

Institutional Activity: Volume patterns suggesting institutional interest, but not strong enough to drive significant price movements.

Correlation Analysis: Correlation with SPY (0.23) indicates a relatively weak correlation between INAB and the broader market.

Relative Valuation: Position within trading range - INAB is currently trading around its 50-day SMA

Key Levels & Action Items

Critical Price Levels:

  • Support at SMA 20 ($1.13)
  • Resistance at SMA 200 ($1.60)

Breakout/Breakdown Levels:

  • Breakout above SMA 200 ($1.60) could signal a new uptrend
  • Breakdown below SMA 20 ($1.13) could indicate further bearish momentum

Time-Sensitive Catalysts: None significant earnings or product launches scheduled

Risk Management: Consider using stop-loss levels at SMA 20 ($1.13) and position sizing considerations based on risk tolerance.

Please note that this is a comprehensive report, and the analysis is based on the provided data. The output format requirements state that I should not provide buy/sell advice, but rather focus on risk/reward analysis only.

Generated

INAB Options Activity & IV Rank

Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 1.3685
Alpha: -61.36%
Correlation: 0.2017
R-Squared: 4.1%
Stock Volatility: 86.5%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own INAB
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$89K
0.00%
#5836 of 6285new13F
Renaissance Technologies Hedge fund
Jim Simons
$17K
0.00%
#3101 of 3138new13F
Rockefeller Capital Management Family office
Rockefeller family
$0K
0.00%
#4683 of 47290.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

INAB Institutional Ownership (13F)

Latest filings — 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

23 filers3,818,283 shares$5.41M value
# Filer Shares Value % of Total % of Float Period
1 Alyeska Investment Group, L.P. 944,319 $1.33M 24.60% — 2026-06-30
2 Franklin Resources, Inc. Custodian 914,531 $1.29M 23.83% — 2026-06-30
3 683 Capital Management, LLC 724,637 $1.02M 18.88% — 2026-06-30
4 Stonepine Capital Management, LLC 695,287 $980.36K 18.11% — 2026-06-30
5 Vanguard Capital Management LLC 88,865 $126.54K 2.34% — 2026-06-30
6 BIOS Capital Management, LP 80,957 $114.15K 2.11% — 2026-06-30
7 Geode Capital Management, LLC Custodian 72,550 $102.30K 1.89% — 2026-06-30
8 Citadel Advisors LLC Custodian 63,055 $88.91K 1.64% — 2026-06-30
9 OPPENHEIMER & CO INC 63,042 $88.89K 1.64% — 2026-06-30
10 Vanguard Group Inc Custodian 28,348 $66.33K 1.23% — 2025-12-31
11 Vanguard Fiduciary Trust Co 43,570 $62.04K 1.15% — 2026-06-30
12 CAPTRUST FINANCIAL ADVISORS 33,295 $46.95K 0.87% — 2026-06-30
13 Texas Capital Bank Wealth Management Services Inc 24,406 $34.41K 0.64% — 2026-06-30
14 Northern Trust Corp Custodian 21,734 $30.64K 0.57% — 2026-06-30
15 RENAISSANCE TECHNOLOGIES LLC 12,100 $17.06K 0.32% — 2026-06-30
16 Tower Research Capital LLC (TRC) Custodian 3,738 $5.27K 0.10% — 2026-06-30
17 Northwestern Mutual Wealth Management Co 2,785 $3.93K 0.07% — 2026-06-30
18 Jones Financial Companies LLLP Custodian 768 $1.04K 0.02% — 2026-06-30
19 SBI Securities Co., Ltd. 100 $133 <0.01% — 2026-09-30
20 BlackRock, Inc. Custodian 84 $118 <0.01% — 2026-06-30
21 Rockefeller Capital Management L.P. Custodian 83 $117 <0.01% — 2026-06-30
22 Barclays PLC Custodian 28 $39 <0.01% — 2026-06-30
23 UBS Group AG Custodian 1 $1 0.00% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

INAB Insider Trading (Form 4)

Latest: 2026-05-29
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-05-29 Emily Fairbairn Director Gift (G) −724,637 — EDGAR
2026-05-12 Luba Greenwood Director Grant (A) +22,000 opt — EDGAR
2026-05-12 William Tai-Wei Ho CEO Grant (A) +154,500 opt — EDGAR
2026-05-12 Patrick McCall CHIEF FINANCIAL OFFICER Grant (A) +56,250 opt — EDGAR
2026-05-12 Jeremy R. Graff Director Grant (A) +22,000 opt — EDGAR
2026-05-12 Lawrence Lamb EVP and CSO Grant (A) +54,000 opt — EDGAR
2026-05-12 Kate Rochlin President and COO Grant (A) +60,000 opt — EDGAR
2026-05-12 Corinne Epperly Director Grant (A) +22,000 opt — EDGAR
2026-05-12 Emily Fairbairn Director Grant (A) +22,000 opt — EDGAR
2026-05-12 Peter C. Brandt Director Grant (A) +22,000 opt — EDGAR
2026-02-06 Kate Rochlin President and COO Grant (A) +80,000 opt — EDGAR
2026-02-06 Lawrence Lamb EVP and CSO Grant (A) +72,000 opt — EDGAR
2026-02-06 Patrick McCall CHIEF FINANCIAL OFFICER Grant (A) +75,000 opt — EDGAR
2026-02-06 William Tai-Wei Ho CEO Grant (A) +206,000 opt — EDGAR
2025-12-23 Patrick McCall CHIEF FINANCIAL OFFICER Award (A) +7,247 $1.38 $10.0K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

INAB Insider Holdings

11 insiders · @ $0.97
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 BIOS Incysus Co-Invest I, LP 10%+ Owner 124,253 $120.0K $0 1 2025-05-07
2 William Tai-Wei Ho CEO 123,601 $119.3K $75.0K 19 2026-05-12
3 Peter C. Brandt Director 98,690 $95.3K $200.0K 13 2026-05-12
4 Alan S. Roemer Director 49,514 $47.8K $50.0K 13 2025-12-23
5 BIOS Equity Partners III, LP Director 19,148 $18.5K $930.1K 3 2025-05-07
6 Patrick McCall CHIEF FINANCIAL OFFICER 9,482 $9.2K $11.0K 17 2026-05-12
7 Kate Rochlin President and COO 9,085 $8.8K $10.0K 15 2026-05-12
8 Lawrence Lamb EVP and CSO 3,379 $3.3K $999 16 2026-05-12
9 Corinne Epperly Director 2,732 $2.6K $0 8 2026-05-12
10 Luba Greenwood Director 261 $252 $999 9 2026-05-12
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

INAB Board & Officers

As of SEC filings through May 29, 2026

Directors 6

Officers 4

10% owners 1

Changes in the last 10 years (92)
Feb 26, 2026The company announced the departure of Alan S. Roemer from the board in an SEC filing
Feb 6, 2026William Tai-Wei Ho listed as CEO (previously President and CEO) in SEC filings
Feb 6, 2026Kate Rochlin listed as President and COO (previously Chief Operating Officer) in SEC filings
May 7, 2025Leslie W. Kreis reported in an SEC filing no longer being a 10% owner
May 7, 2025Cavu Management, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025Cavu Advisors, LLC reported in an SEC filing no longer being a 10% owner
May 7, 2025Bios Equity Partners, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025Bios Equity Partners II, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025Bios Equity COF, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025Bios Clinical Opportunity Fund, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025BP Directors, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025BIOS Incysus Co-Invest I, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025BIOS Fund III, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025BIOS Fund III QP, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025BIOS Fund III NT, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025BIOS Fund II, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025BIOS Fund II QP, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025BIOS Fund II NT, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025BIOS Equity Partners III, LP reported in an SEC filing no longer being a 10% owner
May 7, 2025BIOS Capital Management, LP reported in an SEC filing no longer being a 10% owner
Not reported recently (2)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
1 ETF hold INAB
1 shown · $118.19K total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VXF Vanguard Extended Market ETF Vanguard 0.00% $118,191 — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.